Fig. 1From: Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trialALCAT trial: crossover intervention scheme. Screening (visit 1) and visit 2 can take place on the same date, if patients are not on prohibited medication within 4 weeks prior to enrolment. If patients have received any of the prohibited medications 4 weeks prior to enrolment, a wash-out period of 4 weeks prior to visit 2 (randomization) is required to rule out a carryover effectBack to article page